Venn Life Sciences eyes continued growth after 'impressive hike' in revenues

By Melissa Fassbender contact

- Last updated on GMT

Venn Life Sciences announced interim results for the six months ended June 30, 2016. (Image: iStock/MeePoohyaphoto)
Venn Life Sciences announced interim results for the six months ended June 30, 2016. (Image: iStock/MeePoohyaphoto)

Related tags: Venn life sciences, Contract research organization, Better

With several systems and process improvement initiatives underway, the growing contract research organization (CRO), Venn Life Sciences, continues to look for earnings enhancing opportunities, says CEO.

The company recently released its unaudited interim results for the six months ended June 30, 2016, in which the company posted revenues of €9.06m ($10.18) against H1 2015: €4.25m ($4.77) – an increase Tony Richardson, CEO of Venn Life Sciences, described as “an impressive hike​.”

Additionally, in October 2015 the company acquired​ Kinesis Pharma b.v.

The focus in the first half of this year has been on business stability post-acquisition, cross selling initiatives and integration of certain support functions​,” Richardson told Outsourcing-Pharma.com.

Richard explained the acquisition has been well received by the market, “and with a stable and talented team they can now move into the second phase of business integration and deliver sustainable business growth​.” Initial cross sales have already been achieved as progress continues on the Kinesis integration.

Repositioning for growth

Richardson explained that the main operational challenges are around significant systems and process improvement initiatives currently underway. However, he said the initiatives should result in improved margins and profitability.

Currently, the company is in the process of selling its innovation division, Innovenn.  

This sale will represent the culmination of several months of effort to re-position Innovenn in such a way that will bring better clarity to the performance of the core business, and realize value from the investment in Innovenn​,” said Richardson.

With this, the story will become simpler and the business will be easier to grow​,” he added, explaining that there is a strong pipeline of new opportunities going into the second half of the year and the company continues to see an increase in the average size of project wins.

The company is also continuing to look for “earnings enhancing acquisition opportunities​,” particularly in Central and Eastern Europe.

Moving forward, Richardson said the company will be driven by “good organic growth coupled with further geographic expansion​.”

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars